PreviousNextExpandCollapseSearch

Web Page-Disease

Disease Phase Study No. Summary Status Total
Hide details for Advanced CancersAdvanced Cancers
  87
Hide details for Phase IPhase I
  53
2013-0969   A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND
PHARMACOKINETIC STUDY OF PF-06647263 IN ADULT PATIENTS WITH
ADVANCED SOLID TUMORS
  Open  
2013-0866   A Phase 1, Multi-Center, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMP-514 in Subjects with Advanced Solid Malignancies  Open  
2013-0833   A Phase I Trial of Regorafenib and Cetuximab in Patients with Advanced Malignancy  Open  
2013-0813   A Phase Ib Open-Label, Multi-Center, Dose Escalation and Expansion Study of Orally Administered MEK162 plus BYL719 in Adult Patients with Selected Advanced Solid Tumors   Open  
2013-0709   A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients  Open  
2013-0684   A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection  Open  
2013-0616   A Phase 1 Study of LY3009120 in Patients with Advanced or Metastatic Cancer  Open  
2013-0574   Phase 1 Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignances  Open  
2013-0549   Phase I Safety Study of Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-Refractory Solid Tumor Malignancies  Open  
2013-0525   A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects with Advanced Malignancies  Open  
2013-0466   A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in
Patients With Advanced Solid Tumors or Lymphoma
  Open  
2013-0372   A Phase 1 Pharmacokinetic Study of Oral MLN9708 in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction  Open  
2013-0257   A Phase 1 Multiple Ascending Dose Study of DS-3032b, an oral MDM2 inhibitor, in subjects with advanced solid tumors or lymphomas  Open  
2013-0064   Phase I, Open-Label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects with Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel  Open  
2012-0985   A Phase I open-label dose escalation study with expansion to assess the safety and tolerability of INC280 in patients with c-MET dependent advanced solid tumors  Open  
2012-0795   A Phase I Trial of Ipilimumab (anti CTLA- 4 antibody) in Combination with Lenalidomide (IMiD) in Patients with Advanced Malignancies  Open  
2012-0784   A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients with Advanced Malignancies  Open  
2012-0748   A Phase I Trial of Vemurafenib in Combination with Cetuximab and Irinotecan in Patients with BRAF V600 Mutant Advanced Solid Malignancies  Open  
2012-0721   A Phase I Trial of Dasatinib in Combination with Crizotinib
in Patients with Advanced Malignancies
  Open  
2012-0533   Phase 1 Trial of ADI-PEG 20 plus Cisplatin in Patients with Metastatic Melanoma or other Advanced Solid Malignancies  Open  
2012-0423   A Phase I trial of Dabrafenib (BRAFi) and Pazopanib in patients with BRAF-mutated advanced malignant tumors  Open  
2012-0394   Phase I Study of the Combination of Vemurafenib with Carboplatin and Paclitaxel in Patients with Advanced Malignancy  Open  
2012-0256   Initial Phase I Study of WT2725 Dosing Emulsion in Patients with Advanced Malignancies  Open  
2012-0153   A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf®) in Combination with an mTOR Inhibitor, Everolimus (Afinitor®) or Temsirolimus (Torisel®), in Subjects with Advanced Cancer  Open  
2012-0061   A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination with Valproic Acid or Cetuximab in Patients with Advanced Malignancy   Open  
2011-1183   A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 inhibitor) in Combination with Vemurafenib (BRAF Inhibitor) in Patients with Advanced Malignancies  Open  
2011-1169   Autologous CD19 Specific T-cell Infusion in Patients with B-cell Chronic Lymphocytic Leukemia (B-CLL)  Open  
2011-1159   A Phase 1, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 as a Single-agent and in Combination Therapy in Adult Subjects with Advanced Solid Tumors, Including Small-cell Lung Cancer  Open  
PreviousNextExpandCollapseSearch